RESUMEN
Neuronal ceroid lipofuscinoses (NCLs) are a group of neurodegenerative diseases predominantly in childhood that are characterized by psychomotor deterioration, epilepsy, and early death of patients. The NCLs analyzed in the present study are caused by defects of the specific enzymes, CLN1 (palmitoyl protein thioesterase 1; PPT1), CLN2 (tripeptidyl peptidase 1; TPP1), and CLN10 (cathepsin D). Specific and sensitive diagnostic assays of NCLs were the main goal of this study. They are of increasing importance, particularly since enzyme replacement therapy (ERT) for NCL2 has recently become available for clinical treatment, and ERTs for further NCLs are under development. Here, we report specific and sensitive determinations for CLN1, CLN2, and CLN10 on dried blood spots by tandem mass spectrometry using multiple reaction monitoring mass spectrometry (MRM-MS). Identical substrates suitable for (i) fluorimetric determination of single enzymes and (ii) for MRM-MS determination of multiple enzymes were synthesized by chemical coupling of alkyl-umbelliferone building blocks with the corresponding peptidyl-substrate groups recognized by the target enzyme. Enzymatic determinations were performed both by fluorimetry and MRM-MS in patients with NCL1, NCL2, and NCL10 and showed good agreement in single assays. Moreover, duplex and triplex determinations were successfully performed for NCL1, NCL2, and NCL10. Specific peptidyl-(4-alkyl-umbelliferone) substrates were also synthesized for mass spectrometric determinations of different cathepsins (cathepsins-D, -F, and -B), to provide a differentiation of proteolytic specificities.
Asunto(s)
Pruebas con Sangre Seca/métodos , Fluorometría/métodos , Lipofuscinosis Ceroideas Neuronales/sangre , Espectrometría de Masas en Tándem/métodos , Adolescente , Catepsina D/sangre , Catepsina D/deficiencia , Niño , Preescolar , Humanos , Proteínas de la Membrana/sangre , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Lipofuscinosis Ceroideas Neuronales/enzimología , Proteínas Nucleares/sangre , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Especificidad por Sustrato , Tioléster Hidrolasas/sangre , Tripeptidil Peptidasa 1RESUMEN
BACKGROUND: The neuronal ceroid lipofuscinosis 2 (NCL2) or classic late-infantile neuronal ceroid lipofuscinosis (LINCL) is a neurogenetic disorder caused by mutations in the TPPI gene, which codes for the lysosomal tripeptidyl peptidase 1 (TPPI) EC 3.4.14.9. Loss of functional TPPI activity results in progressive visual and neurological symptoms starting at around 1-2 years of age causing early death. METHODS: We report a DBS-based TPPI assay that cleaves a synthetic tetrapeptide substrate generating a product that is detected by HPLC. Probands and carriers were identified with 100% accuracy (7 probands, 30 carriers, 13 controls). RESULTS: The assay detected a single TPPI activity at a lower pH towards the substrate tested. TPPI activity measurable when extracted at lower pH while inactive at neutral pH showed steady increase for at least 8 h incubation. No loss in TPPI activity was observed when DBS were stored for at least 2 weeks either in freezer, refrigerator, room temperature or 42 °C. CONCLUSION: A sequence variant causing Arg339Gln substitution in a proband had 12% TPPI. TPPI activity can be reliably measured in DBS, giving an opportunity to diagnose NCL2 at birth and refer patients for enzyme replacement or other therapies for earliest intervention, or alternatively offers a second-tier confirmatory test.
Asunto(s)
Aminopeptidasas/metabolismo , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/metabolismo , Pruebas con Sangre Seca , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Serina Proteasas/metabolismo , Aminopeptidasas/sangre , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/sangre , Humanos , Lipofuscinosis Ceroideas Neuronales/enzimología , Serina Proteasas/sangre , Tripeptidil Peptidasa 1RESUMEN
OBJECTIVE: Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, progressive, fatal neurodegenerative pediatric disorder resulting from deficiencies of the lysosomal enzyme tripeptidyl peptidase 1 that are caused by mutations in TPP1. Identifying biomarkers of CLN2 disease progression will be important in assessing the efficacy of therapeutic interventions for this disorder. Neurofilament light is an intrinsic component of healthy neurons; elevated circulating extracellular neurofilament light is a biomarker of neuropathology in several adult-onset neurological diseases. Our objective was to assess whether circulating neurofilament light is a biomarker that is responsive to enzyme replacement therapy (ERT) in CLN2 disease. METHODS: Using an ultrasensitive immunoassay, we assessed plasma neurofilament light changes during disease progression in a canine model of CLN2 disease and in ERT clinical trial CLN2 disease patients. RESULTS: In tripeptidyl peptidase 1 (TPP1)-null dogs (N = 11), but not in control dogs [N = 6 (TPP1+/- ) and N = 27 (WT)], neurofilament light levels increased more than tenfold above initial low baseline levels during disease progression. Before treatment in 21 human subjects with CLN2 disease (age range: 1.72-6.85 years), neurofilament light levels were 48-fold higher (P < 0.001) than in 7 pediatric controls (age range: 8-11 years). Pretreatment neurofilament light did not significantly correlate with disease severity or age. In CLN2 disease subjects receiving ERT, neurofilament light levels decreased by 50% each year over more than 3 years of treatment. INTERPRETATION: Our data indicate that circulating neurofilament light is a treatment-responsive biomarker in CLN2 disease and could contribute to understanding of the pathophysiology of this devastating pediatric disorder.
Asunto(s)
Aminopeptidasas/farmacología , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/farmacología , Progresión de la Enfermedad , Terapia de Reemplazo Enzimático , Proteínas de Neurofilamentos/sangre , Lipofuscinosis Ceroideas Neuronales/sangre , Serina Proteasas/farmacología , Aminopeptidasas/genética , Animales , Animales Modificados Genéticamente , Biomarcadores/sangre , Niño , Preescolar , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/genética , Modelos Animales de Enfermedad , Perros , Femenino , Humanos , Lactante , Masculino , Proteínas de Neurofilamentos/efectos de los fármacos , Lipofuscinosis Ceroideas Neuronales/tratamiento farmacológico , Proteínas Recombinantes/farmacología , Serina Proteasas/genética , Tripeptidil Peptidasa 1RESUMEN
Treatments are emerging for the neuronal ceroid lipofuscinoses (NCLs), a group of similar but genetically distinct lysosomal storage diseases. Clinical ratings scales measure long-term disease progression and response to treatment but clinically useful biomarkers have yet to be identified in these diseases. We have conducted proteomic analyses of brain and cerebrospinal fluid (CSF) from mouse models of the most frequently diagnosed NCL diseases: CLN1 (infantile NCL), CLN2 (classical late infantile NCL) and CLN3 (juvenile NCL). Samples were obtained at different stages of disease progression and proteins quantified using isobaric labeling. In total, 8303 and 4905 proteins were identified from brain and CSF, respectively. We also conduced label-free analyses of brain proteins that contained the mannose 6-phosphate lysosomal targeting modification. In general, we detect few changes at presymptomatic timepoints but later in disease, we detect multiple proteins whose expression is significantly altered in both brain and CSF of CLN1 and CLN2 animals. Many of these proteins are lysosomal in origin or are markers of neuroinflammation, potentially providing clues to underlying pathogenesis and providing promising candidates for further validation.
Asunto(s)
Aminopeptidasas/fisiología , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Encéfalo/metabolismo , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/fisiología , Lisosomas/metabolismo , Glicoproteínas de Membrana/fisiología , Chaperonas Moleculares/fisiología , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Serina Proteasas/fisiología , Tioléster Hidrolasas/fisiología , Animales , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/líquido cefalorraquídeo , Proteoma/análisis , Tripeptidil Peptidasa 1RESUMEN
PURPOSE: CLN2 disease is a genetic disorder caused by dysfunction of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1) that belongs to the neuronal ceroid lipofuscinoses (NCL) and leads to epilepsy, dementia, and death in young persons. CLN2 disease has recently become treatable by enzyme replacement, which can only be effective when the disease is diagnosed early. We have investigated the reliability of a test for TPP1 deficiency in dried blood specimens (DBS) to detect CLN2 disease. RESULTS: During a 12-year period we have received 3882 samples for testing TPP1. Quality of samples was checked by measuring two additional lysosomal enzyme activities. For 50 samples with subnormal TPP1 activity and good sample quality, we obtained adequate clinical and molecular genetic data. All 50 patients had doubtless evidence of CLN2 disease (including seven atypical patients) as shown by clinical findings and the presence of known pathogenic CLN2 variants. Our institution is a major reference center for NCL, and we have never received information that a patient with a normal DBS test was later diagnosed with CLN2 disease. CONCLUSIONS: We consider our TPP1 test on DBS to be a reliable, convenient and inexpensive tool for a first diagnostic step in suspected CLN2 disease.
Asunto(s)
Aminopeptidasas/sangre , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/sangre , Pruebas con Sangre Seca/métodos , Fluorometría/métodos , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/enzimología , Serina Proteasas/sangre , Femenino , Humanos , Masculino , Lipofuscinosis Ceroideas Neuronales/genética , Fenotipo , Factores de Tiempo , Tripeptidil Peptidasa 1RESUMEN
A new tandem mass spectrometry (MS/MS)-based approach for measurement of the enzymatic activity of palmitoyl protein thioesterase I (PPT1) in dried blood spots (DBS) is presented. Deficiency in this enzyme leads to infantile neuronal ceroid lipofuscinosis (INCL, Infantile Batten disease, CLN1). The assay could distinguish between 80 healthy newborns and three previously diagnosed INCL patients. Unlike the fluorimetric PPT1 assay, the MS/MS assay does not require recombinant ß-glucosidase. Furthermore, the assay could be easily combined with a TPP1 enzyme assay (for CLN2 disease) and can be potentially multiplexed with a large panel of additional lysosomal enzyme assays by MS/MS for newborn screening and postscreening analysis.
Asunto(s)
Pruebas con Sangre Seca , Proteínas de la Membrana/sangre , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Tioléster Hidrolasas/sangre , Humanos , Lactante , Proteínas de la Membrana/metabolismo , Estructura Molecular , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/metabolismo , Espectrometría de Masas en Tándem , Tioléster Hidrolasas/metabolismo , Tripeptidil Peptidasa 1RESUMEN
CLN3-Batten disease is a rare, autosomal recessive disorder involving seizures, visual, motor and cognitive decline, and premature death. The Cln3Δex7/8 mouse model recapitulates several phenotypic characteristics of the most common 1.02kb disease-associated deletion. Identification of reproducible biomarker(s) to facilitate longitudinal monitoring of disease progression and provide readouts for therapeutic response has remained elusive. One factor that has complicated the identification of suitable biomarkers in this mouse model has been that variations in animal husbandry appear to significantly influence readouts. In the current study, we cross-compared a number of biological parameters in blood from Cln3Δex7/8 mice and control, non-disease mice on the same genetic background from multiple animal facilities in an attempt to better define a surrogate marker of CLN3-Batten disease. Interestingly, we found that significant differences between Batten and non-disease mice found at one site were generally not maintained across different facilities. Our results suggest that colony variation in the Cln3Δex7/8 mouse model of CLN3-Batten disease can influence potential biomarkers of the disease.
Asunto(s)
Variación Biológica Poblacional , Glicoproteínas de Membrana/genética , Chaperonas Moleculares/genética , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Animales , Biomarcadores/sangre , Estudios de Casos y Controles , Modelos Animales de Enfermedad , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/genéticaRESUMEN
BACKGROUND: We expanded the use of tandem mass spectrometry combined with liquid chromatography (LC-MS/MS) for multiplex newborn screening of seven lysosomal enzymes in dried blood spots (DBS). The new assays are for enzymes responsible for the mucopolysaccharidoses (MPS-I, -II, -IIIB, -IVA, -VI, and -VII) and type 2 neuronal ceroid lipofuscinosis (LINCL). METHODS: New substrates were prepared and characterized for tripeptidyl peptidase 1 (TPP1), α-N-acetylglucosaminidase (NAGLU), and lysosomal ß-glucuronidase (GUSB). These assays were combined with previously developed assays to provide a multiplex LC-MS/MS assay of 7 lysosomal storage diseases. Multiple reaction monitoring of ion dissociations for enzyme products and deuterium-labeled internal standards was used to quantify the enzyme activities. RESULTS: Deidentified DBS samples from 62 nonaffected newborns were analyzed to simultaneously determine (run time 2 min per DBS) the activities of TPP1, NAGLU, and GUSB, along with those for α-iduronidase (IDUA), iduronate-2-sulfatase (I2S), N-acetylgalactosamine-6-sulfatase (GALNS), and N-acetylgalactosamine-4-sulfatase (ARSB). The activities measured in the 7-plex format showed assay response-to-blank-activity ratios (analytical ranges) of 102-909 that clearly separated healthy infants from affected children. CONCLUSIONS: The new multiplex assay provides a robust comprehensive newborn screening assay for the mucopolysaccharidoses. The method has been expanded to include additional lysosomal storage diseases.
Asunto(s)
Pruebas con Sangre Seca/métodos , Enfermedades por Almacenamiento Lisosomal/enzimología , Mucopolisacaridosis/metabolismo , Tamizaje Neonatal/métodos , Lipofuscinosis Ceroideas Neuronales/enzimología , Cromatografía Liquida , Humanos , Recién Nacido , Enfermedades por Almacenamiento Lisosomal/sangre , Enfermedades por Almacenamiento Lisosomal/diagnóstico , Mucopolisacaridosis/sangre , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Espectrometría de Masas en Tándem , Tripeptidil Peptidasa 1RESUMEN
Neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage disorders. NCLs include the rare autosomal recessive neurodegenerative disorder neuronal ceroid lipofuscinosis type 2 (CLN2) disease, caused by mutations in the tripeptidyl peptidase 1 (TPP1)/CLN2 gene and the resulting TPP1 enzyme deficiency. CLN2 disease most commonly presents with seizures and/or ataxia in the late-infantile period (ages 2-4), often in combination with a history of language delay, followed by progressive childhood dementia, motor and visual deterioration, and early death. Atypical phenotypes are characterized by later onset and, in some instances, longer life expectancies. Early diagnosis is important to optimize clinical care and improve outcomes; however, currently, delays in diagnosis are common due to low disease awareness, nonspecific clinical presentation, and limited access to diagnostic testing in some regions. In May 2015, international experts met to recommend best laboratory practices for early diagnosis of CLN2 disease. When clinical signs suggest an NCL, TPP1 enzyme activity should be among the first tests performed (together with the palmitoyl-protein thioesterase enzyme activity assay to rule out CLN1 disease). However, reaching an initial suspicion of an NCL or CLN2 disease can be challenging; thus, use of an epilepsy gene panel for investigation of unexplained seizures in the late-infantile/childhood ages is encouraged. To confirm clinical suspicion of CLN2 disease, the recommended gold standard for laboratory diagnosis is demonstration of deficient TPP1 enzyme activity (in leukocytes, fibroblasts, or dried blood spots) and the identification of causative mutations in each allele of the TPP1/CLN2 gene. When it is not possible to perform both analyses, either demonstration of a) deficient TPP1 enzyme activity in leukocytes or fibroblasts, or b) detection of two pathogenic mutations in trans is diagnostic for CLN2 disease.
Asunto(s)
Aminopeptidasas/sangre , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/sangre , Diagnóstico Precoz , Lipofuscinosis Ceroideas Neuronales/sangre , Serina Proteasas/sangre , Aminopeptidasas/genética , Encéfalo/fisiopatología , Preescolar , Demencia/complicaciones , Demencia/fisiopatología , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas/genética , Pruebas con Sangre Seca , Terapia de Reemplazo Enzimático , Femenino , Humanos , Trastornos del Desarrollo del Lenguaje/complicaciones , Trastornos del Desarrollo del Lenguaje/fisiopatología , Leucocitos/enzimología , Masculino , Mutación , Lipofuscinosis Ceroideas Neuronales/complicaciones , Lipofuscinosis Ceroideas Neuronales/genética , Lipofuscinosis Ceroideas Neuronales/fisiopatología , Fenotipo , Serina Proteasas/genética , Tripeptidil Peptidasa 1RESUMEN
The neuronal ceroid lipofuscinoses (NCLs) are a group of neurodegenerative genetic diseases that primarily affect children and have no known cure. A unified clinical rating scale for the juvenile form of NCL has been developed, although it has not been validated in other subtypes and does not give a true measure of the pathophysiological changes occurring during disease progression. In the present study, we have identified candidate biomarkers in blood plasma of NCL disease using multiple proteomic approaches, with the aim of developing a panel of biomarkers that could serve as a metric for therapeutic response. Candidate biomarkers were identified as proteins with levels that significantly differed between patients and controls in both sample sets. The seven candidates identified have previously been associated with neurodegenerative and inflammatory diseases. Multiplex immunoassay based testing was the most efficient and effective evaluation technique and could be employed on a broad scale to track patient response to treatment.
Asunto(s)
Proteínas Sanguíneas/análisis , Lipofuscinosis Ceroideas Neuronales/sangre , Biomarcadores/sangre , Humanos , Inmunoensayo , ProteómicaRESUMEN
We report new substrates for quantitative enzyme activity measurements of human palmitoyl protein thioesterase (PPT1) and tripeptidyl peptidase (TPP1) in dried blood spots from newborns using tandem mass spectrometry. Deficiencies in these enzyme activities due to inborn errors of metabolism cause neuronal ceroid lipofuscinoses. The assays use synthetic compounds that were designed to mimic the natural substrates. Incubation produces nanomole quantities of enzymatic products per a blood spot that are quantified by tandem mass spectrometry using synthetic internal standards and selected reaction monitoring. The assays utilize a minimum steps for sample workup and can be run in a duplex format for the detection of neuronal ceroid lipofuscinoses or potentially multiplexed with other mass spectrometry-based assays for newborn screening of lysosomal storage disorders.
Asunto(s)
Enfermedades del Recién Nacido/diagnóstico , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Espectrometría de Masas en Tándem/métodos , Tioléster Hidrolasas/sangre , Humanos , Recién Nacido , Enfermedades del Recién Nacido/sangre , Enfermedades del Recién Nacido/enzimología , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/enzimología , Estándares de Referencia , Tripeptidil Peptidasa 1RESUMEN
Both CLN1 and CLN5 deficiencies lead to severe neurodegenerative diseases of childhood, known as neuronal ceroid lipofuscinoses (NCLs). The broadly similar phenotypes of NCL mouse models, and the potential for interactions between NCL proteins, raise the possibility of shared or convergent disease mechanisms. To begin addressing these issues, we have developed a new mouse model lacking both Cln1 and Cln5 genes. These double-knockout (Cln1/5 dko) mice were fertile, showing a slight decrease in expected Mendelian breeding ratios, as well as impaired embryoid body formation by induced pluripotent stem cells derived from Cln1/5 dko fibroblasts. Typical disease manifestations of the NCLs, i.e. seizures and motor dysfunction, were detected at the age of 3 months, earlier than in either single knockout mouse. Pathological analyses revealed a similar exacerbation and earlier onset of disease in Cln1/5 dko mice, which exhibited a pronounced accumulation of autofluorescent storage material. Cortical demyelination and more pronounced glial activation in cortical and thalamic regions was followed by cortical neuron loss. Alterations in lipid metabolism in Cln1/5 dko showed a specific increase in plasma phospholipid transfer protein (PLTP) activity. Finally, gene expression profiling of Cln1/5 dko cortex revealed defects in myelination and immune response pathways, with a prominent downregulation of α-synuclein in Cln1/5 dko mouse brains. The simultaneous loss of both Cln1 and Cln5 genes might enhance the typical pathological phenotypes of these mice by disrupting or downregulating shared or convergent pathogenic pathways, which could potentially include interactions of CLN1 and CLN5.
Asunto(s)
Glicoproteínas de Membrana/metabolismo , Lipofuscinosis Ceroideas Neuronales/metabolismo , Lipofuscinosis Ceroideas Neuronales/patología , Tioléster Hidrolasas/metabolismo , Envejecimiento/patología , Animales , Diferenciación Celular , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Corteza Cerebral/ultraestructura , Cuerpos Embrioides/metabolismo , Cuerpos Embrioides/patología , Femenino , Fluorescencia , Perfilación de la Expresión Génica , Gliosis , Inmunidad/inmunología , Células Madre Pluripotentes Inducidas/metabolismo , Proteínas de Membrana de los Lisosomas , Glicoproteínas de Membrana/deficiencia , Ratones , Ratones Noqueados , Vaina de Mielina/metabolismo , Vaina de Mielina/patología , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/inmunología , Neuronas/metabolismo , Neuronas/patología , Fenotipo , Proteínas de Transferencia de Fosfolípidos/sangre , Fosfolípidos/sangre , Tioléster Hidrolasas/deficiencia , alfa-Sinucleína/metabolismoAsunto(s)
Autoanticuerpos/sangre , Glutamato Descarboxilasa/inmunología , Lipofuscinosis Ceroideas Neuronales/tratamiento farmacológico , Lipofuscinosis Ceroideas Neuronales/inmunología , Prednisolona/administración & dosificación , Adolescente , Factores de Edad , Biomarcadores/sangre , Encéfalo/inmunología , Encéfalo/metabolismo , Encéfalo/fisiopatología , Niño , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Glucocorticoides/administración & dosificación , Humanos , Inteligencia/efectos de los fármacos , Inteligencia/fisiología , Masculino , Trastornos del Movimiento/tratamiento farmacológico , Trastornos del Movimiento/genética , Trastornos del Movimiento/inmunología , Lipofuscinosis Ceroideas Neuronales/sangre , Recuperación de la Función/efectos de los fármacos , Recuperación de la Función/inmunología , Resultado del Tratamiento , Ácido gamma-Aminobutírico/biosíntesisRESUMEN
Neuronal ceroid lipopofuscinosis (Batten disease, NCL) represents a group of common childhood neurodegenerative diseases with a shared feature of deposition of abnormal metabolic products in neurons and other tissues, including peripheral blood lymphocytes. In most forms of NCL no specific enzyme defect is known and the diagnosis relies primarily on ultrastructural identification of characteristic membrane-bound inclusions containing the abnormal metabolic product. All buffy-coat specimens examined during a 7-year period (1997-2004) for the exclusion or confirmation of the diagnosis NCL were reviewed. From a total of 265 samples, 9 were inadequate and NCL was diagnosed in 56. Five showed granular osmophilic deposits of infantile Batten disease (NCL1), 10 showed curvilinear profiles of classical late infantile Batten disease (NCL2), and 17 showed vacuolated lymphocytes with fingerprint profiles, indicating classical juvenile Batten disease (NCL3). 24 samples (43%) demonstrated compact electron-dense deposits with fingerprint profiles in the absence of vacuolated lymphocytes, indicative of variant forms NCL. Ultrastructual examination of peripheral blood allows reliable and specific diagnosis of subtypes of Batten disease, including variants, and is a useful, minimally invasive test for the diagnosis of NCL in childhood.
Asunto(s)
Ceroide/metabolismo , Cuerpos de Inclusión/ultraestructura , Leucocitos Mononucleares/ultraestructura , Microscopía Electrónica de Transmisión , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Preescolar , Humanos , Cuerpos de Inclusión/metabolismo , Lactante , Leucocitos Mononucleares/metabolismo , Lipofuscinosis Ceroideas Neuronales/sangreAsunto(s)
Pruebas Enzimáticas Clínicas , Endopeptidasas/sangre , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Tioléster Hidrolasas/sangre , Aminopeptidasas , Recolección de Muestras de Sangre , Niño , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas , Endopeptidasas/deficiencia , Humanos , Lipofuscinosis Ceroideas Neuronales/sangre , Serina Proteasas , Tioléster Hidrolasas/deficiencia , Tripeptidil Peptidasa 1RESUMEN
The mnd mouse, a model of neuronal ceroid lipofusinosis (NCL), has a profound vitamin E deficiency in sera and brain, associated with cerebral deterioration characteristic of NCL. In this study, the vitamin E deficiency is corrected using dietary supplementation. However, the histopathological features associated with NCL remained. With use of a bioinformatics approach based on high-resolution solid and solution state 1H-NMR spectroscopy and principal component analysis (PCA), the deficits associated with NCL are defined in terms of a metabolic phenotype. Although vitamin E supplementation reversed some of the metabolic abnormalities, in particular the concentration of phenylalanine in extracts of cerebral tissue, PCA demonstrated that metabolic deficits associated with NCL were greater than any effects produced from vitamin E supplementation. These deficits included increased glutamate and N-acetyl-L-aspartate and decreased creatine and glutamine concentrations in aqueous extracts of the cortex, as well as profound accumulation of lipid in intact cerebral tissue. This is discussed in terms of faulty production of mitochondrial-associated membranes, thought to be central to the deficits in mnd mice.
Asunto(s)
Biología Computacional/métodos , Lipofuscinosis Ceroideas Neuronales/metabolismo , Deficiencia de Vitamina E/metabolismo , Animales , Encéfalo/metabolismo , Encéfalo/patología , Corteza Cerebral/química , Suplementos Dietéticos , Espectroscopía de Resonancia Magnética , Proteínas de la Membrana/genética , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes Neurológicos , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/patología , Fenotipo , Análisis de Componente Principal , Vitamina E/administración & dosificación , Vitamina E/análisis , Vitamina E/uso terapéutico , Deficiencia de Vitamina E/terapiaRESUMEN
OBJECTIVE: To determine whether the late onset form of inherited ceroid lipofuscinosis (CL) in Tibetan Terriers is accompanied by low plasma carnitine concentrations prior to the appearance of clinical signs. ANIMALS: 129 healthy Tibetan Terriers, 12 Tibetan Terriers with CL, and 95 healthy purebred dogs of other breeds. PROCEDURE: After withholding food, blood samples were collected from all dogs into tubes containing EDTA. Blood samples were analyzed for plasma-free carnitine and acyl-carnitines concentrations. RESULTS: Neither the mean plasma total carnitine concentration nor the mean fraction of carnitine in the free form differed significantly between Tibetan Terriers with CL and healthy Tibetan Terriers. Among Tibetan Terriers and the general dog population, plasma carnitine concentration increased with age. Castrated males had an overall increase in plasma carnitine concentrations and variability, compared with sexually intact males. By comparison, plasma carnitine concentrations were not significantly different between spayed and sexually intact females. The mean plasma carnitine concentration in the Tibetan Terriers was approximately 22% higher than in the general population of healthy dogs of other breeds. CONCLUSIONS AND CLINICAL RELEVANCE: Contrary to what is seen in early onset CL in English Setters and in humans with some forms of CL, plasma carnitine concentrations are not decreased in the late-onset disorder in Tibetan Terriers. Our large-scale study establishes reference range values for plasma carnitine concentrations in dogs as functions of age and sex that will be useful in evaluating potential carnitine deficiencies in other disorders in dogs.
Asunto(s)
Carnitina/análogos & derivados , Carnitina/sangre , Enfermedades de los Perros/sangre , Lipofuscinosis Ceroideas Neuronales/veterinaria , Factores de Edad , Animales , Corteza Cerebral/patología , Corteza Cerebral/ultraestructura , Enfermedades de los Perros/patología , Perros , Femenino , Masculino , Microscopía Electrónica/veterinaria , Microscopía Fluorescente/veterinaria , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/patología , Retina/patología , Retina/ultraestructura , Factores SexualesAsunto(s)
Endopeptidasas/sangre , Lipofuscinosis Ceroideas Neuronales/diagnóstico , Péptido Hidrolasas/genética , Aminopeptidasas , Biomarcadores/sangre , Pruebas Enzimáticas Clínicas , Dipeptidil-Peptidasas y Tripeptidil-Peptidasas , Humanos , Lactante , Lipofuscinosis Ceroideas Neuronales/sangre , Lipofuscinosis Ceroideas Neuronales/genética , Pepstatinas/farmacología , Inhibidores de Proteasas/farmacología , Serina Proteasas , Tripeptidil Peptidasa 1RESUMEN
We identified a novel nonsense CLN2 mutation (Q509X) in three Italian children with classical late-infantile neuronal ceroid lipofuscinosis (LINCL) from two unrelated families. The mutation introduced a premature stop codon in exon 12 of the CLN2 gene, resulting in a protein lacking the last 54 residues. Haplotype analysis suggested independent origin of the mutation in our families. The protein truncation test was employed to verify the functional consequences of the novel Q509X mutation. In Patient 1, the mutant alleles were transcribed but translated in a shorted peptide suggesting that the Q509X mutation is likely to interfere with CLN2p function. While expanding the list of genetic variants in LINCL, our findings represent the first molecular characterization of LINCL patients in South Europe.